AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 51 min read$COYA

Coya Therapeutics: Fully Enrolled 120-Patient Phase 2/3 ALSTARS Trial; Topline Data Expected Q2 2027

Coya Therapeutics (COYA) completed enrollment of 120 patients in its Phase 2/3 ALSTARS trial for COYA 302, a treatment for ALS. Topline data is expected in early Q2 2027. The study compares two dosing regimens against placebo, with primary endpoint being change in ALSFRS-R score. Patients may enter a 24-week extension phase.

Original reporting
tradingview.com
Published Oct 5, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 12:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Coya Therapeutics: Fully Enrolled 120-Patient Phase 2/3 ALSTARS Trial; Topline Data Expected Q2 2027 — source image
Source · tradingview.com
Decision brief

The 30-second read

$COYABullishLow
01

Why it matters

The enrollment milestone reduces execution uncertainty and may attract short‑term buying interest ahead of the Q2 2027 data release.

02

Market read

First‑report trial enrollment news, modestly bullish for COYA and ALS biotech peers.

03

What to watch

Potential delays in data readout or regulatory scrutiny could dampen upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Coya Therapeutics (COYA) is a clinical‑stage biotech focused on ALS therapies.

Company-level read

Ticker impact

$COYABullishHigh confidence
Context

Coya Therapeutics announced full enrollment of its 120‑patient Phase 2/3 ALSTARS trial, a first‑report clinical update.

Expected impact

modest upside as investors price in potential positive trial results

Evidence & confidence

First disclosure of full enrollment reduces execution risk and sets the stage for Q2 2027 data release.

Market effects

Sector

Positive signal for the ALS biotech sub‑sector, may lift peer valuations.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minor, confined to specialty pharma market.

Counterpoint

What could challenge this read

If trial data later disappoint, early enrollment hype could reverse quickly.

Key entities

  • company
    Coya Therapeutics

    Biotech developing COYA 302 for ALS.

Read at source← All news

StoryCoya completes enrollment for late-stage ALS study

Related articles

OCT 6
$COYAHighAI 8/10

Coya Therapeutics stock reiterated at Buy by H.C. Wainwright on trial enrollment

H.C. Wainwright reiterated a Buy rating on Coya Therapeutics (COYA) with a $18.00 price target, citing full enrollment in its Phase 2/3 ALSTARS trial for ALS treatment. The stock trades at $4.85, suggesting over 270% upside. The trial aims to evaluate COYA 302's efficacy and safety, with top-line data expected in early Q2 2027. The company holds more cash than debt, providing financial flexibility.

investing.com1 min
OCT 5
$COYAMedAI 8/10

Coya Gains on Test News

Coya Therapeutics (COYA) announced full enrollment of 120 participants in its Phase 2/3 ALSTARS Trial for ALS treatment. Topline data is expected in early Q2 2027. CEO Arun Swaminathan highlighted the milestone and the potential insights from the trial.

baystreet.ca2 min
OCT 5
$COYALow

Coya Therapeutics, Inc. issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase…

Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 5, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Compa

SEC EDGAR 8-K1 min
OCT 5
$COYALowAI 8/10

Coya completes enrollment in ALS trial, data due early Q2 2027

Coya Therapeutics (COYA) completed enrollment in its Phase 2/3 ALSTARS trial for ALS treatment COYA 302, with 120 participants. Topline data is expected in early Q2 2027. The trial is a randomized, placebo-controlled study with primary endpoints measuring disease severity. COYA 302 has FDA Fast Track designation. Coya partnered with Dr. Reddy’s for commercialization outside Japan, South America, and Mexico.

investing.com1 min
SEP 15
$COYALowAI 8/10

Coya Therapeutics, Inc. issued a press release announcing that the one hundredth (100 th ) patient has been enrolled in the Company’s ongoing Phase 2/3…

Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 15, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing that the one hundredth (100 th ) patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Company’s co

SEC EDGAR 8-K1 min